Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation

Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation

(1) <b>Background</b>: TNF inhibitors (TNFis) have revolutionized the treatment of rheumatoid arthritis (RA). However, 30–40% of RA patients do not respond adequately to those biologics. In addition to neutralizing soluble TNF, TNFis have the ability to bind the transmembrane form of TNF...

Full description

Saved in:
Bibliographic Details
Main Authors: Katy Diallo, Yannick Degboé, Michel Baron, Anaïs Bellin-Robert, Jean-Frédéric Boyer, Adeline Ruyssen-Witrand, Arnaud Constantin, Benjamin Rauwel, Alain Cantagrel, Jean-Luc Davignon
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Diagnostics
Subjects:
rheumatoid arthritis
anti-TNF
Nrf2
reverse signaling
biotherapy
monoclonal antibodies
Online Access:https://www.mdpi.com/2075-4418/15/10/1232
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2075-4418/15/10/1232

Similar Items